FINWIRES · TerminalLIVE
FINWIRES

研究快讯:PTC上调2026财年每股收益预期,受益于股票回购和利润率扩张

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:PTC公布的2026财年第二季度(3月季度)业绩远超市场预期,销售额达7.74亿美元(同比增长22%),高于预期的7.13亿美元;非GAAP每股收益为2.69美元(高于预期的2.11美元),同比增长50%,主要得益于非GAAP营业利润率同比增长600个基点至53%。按固定汇率计算,年度经常性收入(ARR)增长8.5%至23.9亿美元,达到PTC此前预期的上限,但较第一季度的9.0%有所放缓;经营现金流增长14%至3.21亿美元(高于第一季度的13%)。管理层维持2026财年年度经常性收入(ARR)增长预期在7.5%-9.5%之间,自由现金流(FCF)预期维持在8.5亿美元,但将非GAAP每股收益(EPS)中值从7.60美元上调至7.78美元。我们认为,加速的股票回购活动将对业绩构成支撑,其中包括第二季度6.25亿美元的回购以及2026财年计划的12.75亿美元回购,这反映出强劲的现金流生成能力以及对股东回报的承诺,同时保持了保守的债务与EBITDA比率(第二季度末为0.8倍)。3月份完成的Kepware和ThingWorx剥离将使PTC能够更加专注于核心CAD、PLM和ALM解决方案。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661
研究快讯:PTC上调2026财年每股收益预期,受益于股票回购和利润率扩张 | FINWIRES